Brief: BioArctic Says Leqembi Approved For The Treatment Of Alzheimer's Disease In UAE
14/08/2024 24:02
Aug 13 (Reuters) - BioArctic AB BIOAb.ST :
* LEQEMBI APPROVED FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IN THE
UNITED ARAB EMIRATES
* BIOARCTIC AB - IN CLARITY AD STUDY, LEQEMBI MET ITS
PRIMARY
ENDPOINT AND ALL KEY SECONDARY ENDPOINTS WITH STATISTICALLY
SIGNIFICANT RESULTS
Source text for Eikon: ID:nWkr4m0SZS
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln